Table 2 Comparison of clinicopathologic characteristics between patients with and without early recurrence (ER).
From: Nomogram for predicting early recurrence of hepatocellular carcinoma with narrow resection margin
Variables | Non-ER (n = 1585) | ER (n = 1372) | p-value |
|---|---|---|---|
Age, years | |||
< 60 | 1154 (72.8%) | 1012 (73.8%) | 0.588 |
≥ 60 | 431 (27.2%) | 360 (26.2%) | |
Gender | |||
Female | 235 (14.8%) | 181 (13.2%) | 0.222 |
Male | 1350 (85.2%) | 1191 (86.8%) | |
Smoking | |||
No | 1008 (63.6%) | 881 (64.2%) | 0.757 |
Yes | 577 (36.4%) | 491 (35.8%) | |
Alcohol consumption | |||
No | 1266 (79.9%) | 1083 (78.9%) | 0.559 |
Yes | 319 (20.1%) | 289 (21.1%) | |
Hypertension | |||
No | 1359 (85.7%) | 1210 (88.2%) | 0.056 |
Yes | 226 (14.3%) | 162 (11.8%) | |
Diabetes Mellitus | |||
No | 1487 (93.8%) | 1296 (94.5%) | 0.507 |
Yes | 98 (6.2%) | 76 (5.5%) | |
Liver cirrhosis | |||
Absence | 465 (29.3%) | 427 (31.1%) | 0.310 |
Presence | 1120 (70.7%) | 945 (68.9%) | |
HBsAg | |||
Negative | 201 (12.7%) | 143 (10.4%) | 0.064 |
Positive | 1384 (87.3%) | 1229 (89.6%) | |
AFP, µg/L | |||
< 400 | 1188 (75.0%) | 785 (57.2%) | < 0.001 |
≥ 400 | 397 (25.0%) | 587 (42.8%) | |
HBVDNA, IU/mL | |||
< 1000 | 240 (15.1%) | 173 (12.6%) | 0.054 |
≥ 1000 | 1345 (84.9%) | 1199 (87.4%) | |
WBC, × 109/L | |||
< 4 | 345 (21.8%) | 254 (18.5%) | 0.032 |
≥ 4 | 1384 (87.3%) | 1229 (89.6%) | |
BCLC staging system | |||
0 | 87 (5.5%) | 17 (1.2%) | < 0.001 |
A | 1356 (85.6%) | 1008 (73.5%) | |
B | 142 (9.0%) | 347 (25.3%) | |
AJCC 8th staging system | |||
Ia | 105 (6.6%) | 20 (1.5%) | < 0.001 |
Ib | 1036 (65.4%) | 565 (41.2%) | |
IIa | 392 (24.7%) | 540 (39.4%) | |
IIb | 52 (3.3%) | 247 (18.0%) | |
PLT, × 109/L | |||
< 100 | 257 (16.2%) | 210 (15.3%) | 0.532 |
≥ 100 | 1328 (83.8%) | 1162 (84.7%) | |
ALB, g/L | |||
< 35 | 26 (1.6%) | 46 (3.4%) | 0.004 |
≥ 35 | 1559 (98.4%) | 1326 (96.6%) | |
TBIL, µmol/L | |||
< 17 | 1214 (76.6%) | 1023 (74.6%) | 0.215 |
≥ 17 | 371 (23.4%) | 349 (25.4%) | |
GGT, U/L | |||
< 50 | 769 (48.5%) | 417 (30.4%) | < 0.001 |
≥ 50 | 816 (51.5%) | 955 (69.6%) | |
ALP, U/L | |||
< 80 | 869 (54.8%) | 512 (37.3%) | < 0.001 |
≥ 80 | 716 (45.2%) | 860 (62.7%) | |
ALBI grade | |||
I | 1293 (81.6%) | 1018 (74.2%) | < 0.001 |
II | 292 (18.4%) | 354 (25.8%) | |
Surgical method | |||
Minor hepatectomy | 1395 (88.0%) | 918 (66.9%) | < 0.001 |
Major hepatectomy | 190 (12.0%) | 454 (33.1%) | |
Blood transfusion | |||
No | 1500 (94.6%) | 1182 (86.2%) | < 0.001 |
Yes | 85 (5.4%) | 190 (13.8%) | |
Operative bleeding loss, mL | |||
No | 1512 (95.4%) | 1219 (88.8%) | < 0.001 |
Yes | 73 (4.6%) | 153 (11.2%) | |
Tumor size, cm | |||
< 5 | 950 (59.9%) | 410 (29.9%) | < 0.001 |
5–10 | 502 (31.7%) | 623 (45.4%) | |
> 10 | 133 (8.4%) | 339 (24.7%) | |
Tumor number | |||
Single | 1401 (88.4%) | 992 (72.3%) | < 0.001 |
Multiple | 184 (11.6%) | 380 (27.7%) | |
Microvascular invasion | |||
Absence | 1242 (78.4%) | 772 (56.3%) | < 0.001 |
Presence | 343 (21.6%) | 600 (43.7%) | |
Edmondson-Steiner grade | |||
I-II | 286 (18.0%) | 124 (9.0%) | < 0.001 |
III-IV | 1299 (82.0%) | 1248 (91.0%) | |
Tumor capsular | |||
Absence | 187 (11.8%) | 248 (18.1%) | < 0.001 |
Presence | 1398 (88.2%) | 1124 (81.9%) | |
Satellite nodules | |||
Absence | 1139 (71.9%) | 715 (52.1%) | < 0.001 |
Presence | 446 (28.1%) | 657 (47.9%) | |
Antiviral therapy | |||
No | 542 (34.2%) | 607 (44.2%) | < 0.001 |
Yes | 1043 (65.8%) | 765 (55.8%) | |
Postoperative TACE | |||
No | 1007 (63.5%) | 816 (59.5%) | 0.026 |
Yes | 578 (36.5%) | 556 (40.5%) |
